HC Wainwright Predicts Valneva’s Q4 Earnings (NASDAQ:VALN)

Valneva SE (NASDAQ:VALN) – Stock analysts at HC Wainwright lowered their Q4 2024 EPS estimates for shares of Valneva in a report issued on Wednesday, February 19th. HC Wainwright analyst E. White now anticipates that the company will post earnings per share of ($0.17) for the quarter, down from their previous estimate of ($0.15). HC Wainwright has a “Buy” rating and a $17.00 price objective on the stock. The consensus estimate for Valneva’s current full-year earnings is $0.13 per share. HC Wainwright also issued estimates for Valneva’s Q1 2025 earnings at ($0.40) EPS, Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.33) EPS, FY2025 earnings at ($1.36) EPS, FY2026 earnings at ($1.23) EPS and FY2027 earnings at ($1.28) EPS.

Valneva Trading Down 5.9 %

Valneva stock opened at $7.44 on Friday. The stock has a market cap of $604.57 million, a PE ratio of -57.23 and a beta of 1.98. Valneva has a 52 week low of $3.62 and a 52 week high of $9.50. The company has a current ratio of 2.78, a quick ratio of 2.25 and a debt-to-equity ratio of 0.70. The stock has a 50-day moving average price of $5.25 and a 200 day moving average price of $5.67.

Institutional Trading of Valneva

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Wells Fargo & Company MN grew its holdings in Valneva by 14.3% in the fourth quarter. Wells Fargo & Company MN now owns 246,766 shares of the company’s stock valued at $1,079,000 after purchasing an additional 30,859 shares during the period. AlphaCentric Advisors LLC grew its stake in shares of Valneva by 33.7% during the 3rd quarter. AlphaCentric Advisors LLC now owns 118,000 shares of the company’s stock valued at $717,000 after buying an additional 29,748 shares during the period. Finally, ABC Arbitrage SA purchased a new stake in shares of Valneva during the 4th quarter valued at $84,000. Hedge funds and other institutional investors own 11.39% of the company’s stock.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.